v3.22.2.2

Significant Transactions (Narrative) (Details) - USD ($) |  |  |  | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Mar. 16, 2022 | Nov. 01, 2021 | Aug. 23, 2021 | Jun. 30, 2022 | Sep. 30, 2021
Amortization of deferred financing costs |  |  |  | $ 107,000 |
Impairment of investment in equity security |  |  |  | 1,760,000 |
College Station Investors LLC And Bryan Capital [Member] |  |  |  |  |
Total purchase price |  | $ 28,750,000 |  |  |
Cash payment |  | 28,000,000 |  |  |
Fair market value of property |  | $ 151,450 |  |  |
Percentage of base rent |  | 6.50% |  |  |
Cash consideration for equity interest acquired |  | $ 50,000 |  |  |
Number of warrants issued |  | 51,583 |  |  |
Warrants, exercise price per share |  | $ 33.25 |  |  |
Shares issued under the Warrant |  | 11,583 |  |  |
Fair value of the warrant |  | $ 217,255 |  |  |
College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan |  |  |  |  |
Secured term loan |  | $ 22,375,000 |  |  |
Interest rate (as percent) |  | 3.25% |  |  |
Unrestricted cash |  | $ 10,000,000 |  |  |
Irrevocable letter of credit |  | 5,469,000 |  |  |
Cost incurred to attain debt |  | $ 214,000 |  |  |
Interest expense |  |  |  | 489,000 |
Amortization of deferred financing costs |  |  |  | 107,000 |
College Station Investors LLC And Bryan Capital [Member] | IBio CMO Preferred Tracking Stock |  |  |  |  |
Warrants issuable |  | 1 |  |  |
Percentage of equity interest |  | 0.01% |  |  |
Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member] |  |  |  |  |
Collaboration and license agreement, notice duration to terminate contract |  |  | 30 days |  |
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member] |  |  |  |  |
Collaboration and license agreement, royalty payment term |  |  | 10 years |  |
Collaboration and license agreement, period to cure breach of contract |  |  | 60 days |  |
Collaboration and license agreement, notice duration to terminate contract |  |  | 90 days |  |
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Event of Non-Payment [Member] | RubrYc Theraputics, Inc. [Member] |  |  |  |  |
Collaboration and license agreement, period to cure breach of contract |  |  | 30 days |  |
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Clinical Development and Regulatory Milestone Payments [Member] | RubrYc Theraputics, Inc. [Member] |  |  |  |  |
Milestone payments |  |  | $ 15,000,000 |  |
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member] |  |  |  |  |
Collaboration and license agreement, period to cure breach of contract |  |  | 60 days |  |
Collaboration and license agreement, notice duration to terminate contract |  |  | 90 days |  |
Collaboration and license agreement, agreement term |  |  | 5 years |  |
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Event of Non-Payment [Member] | RubrYc Theraputics, Inc. [Member] |  |  |  |  |
Collaboration and license agreement, period to cure breach of contract |  |  | 30 days |  |
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Financing Requirement not Met [Member] | RubrYc Theraputics, Inc. [Member] |  |  |  |  |
Collaboration and license agreement, notice duration to terminate contract |  |  | 30 days |  |
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Clinical Development and Regulatory Milestone Payments [Member] | RubrYc Theraputics, Inc. [Member] |  |  |  |  |
Milestone payments |  |  | $ 15,000,000 |  |
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | No Biosimilar Product has been Approved [Member] | RubrYc Theraputics, Inc. [Member] |  |  |  |  |
Collaboration and license agreement, royalty payment term |  |  | 10 years |  |
Series A-2 Preferred Stock [Member] | Stock Purchase Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member] |  |  |  |  |
Stock purchase agreement, number of shares purchased | 954,782 |  | 1,909,563 |  |
Stock purchase agreement, value of shares purchased | $ 2,500,000 |  | $ 5,000,000 |  |
Stock purchase agreement, number of shares to be purchased |  |  | 954,782 |  |
Stock purchase agreement, value of shares to be purchased |  |  | $ 2,500,000 |  |
Preferential dividend rate percentage |  |  | 8.00% |  |
Minimum required shares to be eligible for preferential dividend rate |  |  | 1,500,000 |  |
Proceeds from conversion of preferred stock to common stock |  |  | $ 30,000,000 |  |
Liability for the assumed acquisition |  |  |  |  | $ 2,500,000
Impairment of investment in equity security |  |  |  | 1,760,000 |
Impairment of current prepaid expense |  |  |  | 288,000 |
Impairment of non-current prepaid expense |  |  |  | $ 864,000 |

X
- Definition Amount of base rent payable on percentage of fair Market Value of the Property. + References No definition available. + Details
Name: | ibio_BaseRentPercentageOfFairMarketValueOfProperty
Namespace Prefix: | ibio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration and license agreement, agreement term + References No definition available. + Details
Name: | ibio_CollaborationAndLicenseAgreementAgreementTerm
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration and license agreement, notice duration to terminate contract + References No definition available. + Details
Name: | ibio_CollaborationAndLicenseAgreementNoticeDurationToTerminateContract
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration and license agreement, period to cure breach of contract + References No definition available. + Details
Name: | ibio_CollaborationAndLicenseAgreementPeriodToCureBreachOfContract
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration and license agreement, royalty payment term + References No definition available. + Details
Name: | ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of milestone payments based on different scenarios. + References No definition available. + Details
Name: | ibio_CollaborativeArrangementMilestonePayments
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Threshold limit of unrestricted cash to be maintained. + References No definition available. + Details
Name: | ibio_CreditAgreementThresholdLimitUnrestrictedCash
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amortization of loan and debt issuance costs. + References No definition available. + Details
Name: | ibio_DeferredFinancingCostsAmortizationExpense
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Consideration transferred for equity interest acquired under the equity agreement. + References No definition available. + Details
Name: | ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Equity agreement, percentage of equity interest issued or issuable. + References No definition available. + Details
Name: | ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable
Namespace Prefix: | ibio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Warrants issued or issuable under the equity agreement. + References No definition available. + Details
Name: | ibio_EquityAgreementWarrantsIssuedOrIssuable
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair market value of the property. + References No definition available. + Details
Name: | ibio_FairMarketValueOfProperty
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Impairment of current prepaid expenses. + References No definition available. + Details
Name: | ibio_ImpairmentOfPrepaidExpensesCurrent
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Impairment of non-current prepaid expenses. + References No definition available. + Details
Name: | ibio_ImpairmentOfPrepaidExpensesNonCurrent
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Irrevocable letter of credit + References No definition available. + Details
Name: | ibio_IrrevocableLetterOfCredit
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Minimum required shares to be eligible for preferential dividend rate + References No definition available. + Details
Name: | ibio_MinimumRequiredSharesToBeEligibleForPreferentialDividendRate
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests. + References No definition available. + Details
Name: | ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash payment for purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests. + References No definition available. + Details
Name: | ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Stock purchase agreement, number of shares purchased + References No definition available. + Details
Name: | ibio_StockPurchaseAgreementNumberOfSharesPurchased
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Stock purchase agreement, number of shares to be purchased + References No definition available. + Details
Name: | ibio_StockPurchaseAgreementNumberOfSharesToBePurchased
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Stock purchase agreement, value of shares purchased + References No definition available. + Details
Name: | ibio_StockPurchaseAgreementValueOfSharesPurchased
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Stock purchase agreement, value of shares to be purchased + References No definition available. + Details
Name: | ibio_StockPurchaseAgreementValueOfSharesToBePurchased
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of warrants issued for the final payment of rent due under sublease. + References No definition available. + Details
Name: | ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of warrants issued for the final payment of rent due under sublease. + References No definition available. + Details
Name: | ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized from contingent consideration in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 15 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492 + Details
Name: | us-gaap_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 55 -Paragraph 69C -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 55 -Paragraph 69B -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contractual interest rate for funds borrowed, under the debt agreement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1B -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1D -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399 + Details
Name: | us-gaap_DeferredFinanceCostsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 8A -URI https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562 + Details
Name: | us-gaap_ImpairmentOfInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of the cost of borrowed funds accounted for as interest expense for debt. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 6 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 55 -Paragraph 69F -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 55 -Paragraph 69E -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1F -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611 + Details
Name: | us-gaap_InterestExpenseDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage rate used to calculate dividend payments on preferred stock. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 + Details
Name: | us-gaap_PreferredStockDividendRatePercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=ibio_IbioCmoPreferredTrackingStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ibio_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=ibio_EventOfNonPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=ibio_ClinicalDevelopmentAndRegulatoryMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=ibio_FinancingRequirementNotMetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=ibio_NoBiosimilarProductHasBeenApprovedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |